BIIB CHMP opinion: Thursday, July 23, 2026
Variation type II · TECFIDERA · Submission of the final study results from 109MS306 (CONNECT) Part 2 listed as a category 3 study in the RMP; this is a phase 3 efficacy and safety study of BG00012 in pediatric subjects with relapsing-remitting multiple sclerosis (RRMS). The primary objective of Part
Dates are sourced from official registries and filings and can change — estimated dates (marked ~) slip routinely. This page updates automatically when the source registry moves the date. Research information only, not investment advice.
Every date on this page is free — forever.
A free account adds the interactive calendar with US/EU filters and watchlists. Investor (€19/mo) adds Impact Forecasts on each event, date-slip tracking and calendar sync (Google/Apple/Outlook). Pro adds the full analytics stack.